https://www.propublica.org/article/hhs-alicia-jackson-menopause-treatment-policy
Friday, October 30, 2026
U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In — ProPublica
Alicia Jackson endorsed a key FDA policy change on hormone replacement therapies while holding at least $115,000 in stock in a company providing access to menopause treatments. Ethics experts called her endorsement an “obvious conflict of interest.”…
Subscribe to:
Post Comments (Atom)
Click Older Posts above to see more.
No comments:
Post a Comment